Skip to content

A new avenue for treating neuronal diseases: Ceftriaxone, an old antibiotic demonstrating behavioral neuronal effects

Research output: Contribution to journalReview article

Original languageEnglish
Pages (from-to)149-156
Number of pages8
JournalBehavioural Brain Research
Volume364
Early online date12 Feb 2019
DOIs
DateAccepted/In press - 12 Feb 2019
DateE-pub ahead of print - 12 Feb 2019
DatePublished (current) - 17 May 2019

Abstract

Several neurodegenerative disorders, namely Parkinson's disease dementia, dementia with Lewy bodies, and Alzheimer's disease, share common pathophysiological features, such as (1) cognitive deficits, (2) glutamatergic hyperactivity-related excitotoxicity, and (3) deposition of α-synuclein (α-syn) and β-amyloid (Aβ). Ceftriaxone (CEF) is a well-tested and safe drug that has been used as an antibiotic for several decades. Recent studies have demonstrated the following effects of CEF: (1) increasing glutamate transporter-1 expression and glutamate reuptake and suppressing excitotoxicity, (2) binding well with α-syn and inhibition of α-syn polymerization, (3) modulating expression of genes related to Aβ metabolism, and (4) enhancing neurogenesis and recovery of neuronal density. In addition, our data revealed that CEF ameliorates seizure and abnormal neuronal firing in the brain. These results suggest the potential of CEF in treating neuronal disorders. This paper addresses the effects and pharmacology of CEF.

    Research areas

  • Neurodegenerative Disorders, Parkinson's disease dementia, dementia with lewy bodies, Alzheimer's disease, cetriaxone

Documents

Documents

  • Full-text PDF (accepted author manuscript)

    Rights statement: This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at https://www.sciencedirect.com/science/article/pii/S016643281831605X. Please refer to any applicable terms of use of the publisher.

    Accepted author manuscript, 1 MB, PDF document

    Embargo ends: 12/02/20

    Request copy

    Licence: Unspecified

DOI

View research connections

Related faculties, schools or groups